Target family: Leukotriene receptors (type: gpcr)
Target: BLT<sub>1</sub> receptor

Ligand: U75302 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.4 pKi
Reference (Journal): Characterization of the cloned guinea pig leukotriene B4 receptor: comparison to its human orthologue.
Published in: Eur J Pharmacol

Ligand: [3H]LTB4 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 9.8 pKd
Reference (Journal): A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis.
Published in: Nature

Ligand: [3H]LTB4 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 9.2 pKd
Reference (Journal): Cloning and characterization of rat leukotriene B(4) receptor.
Published in: Biochem Biophys Res Commun

Ligand: [3H]LTB4 (Synthetic organic)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 9.2 pKd
Reference (Journal): Molecular and biological characterization of the murine leukotriene B4 receptor expressed on eosinophils.
Published in: J Exp Med

Ligand: [3H]CGS23131 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.9 pKd
Reference (Journal): Comparison of antagonist and agonist binding to the leukotriene B4 receptor intact human polymorphonuclear neutrophils (PMN).
Published in: J Pharmacol Exp Ther

Ligand: SC-41930 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.1 pIC50
Reference (Journal): Blockade of human neutrophil activation by 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]propoxy]phenoxy]benzoic acid (LY293111), a novel leukotriene B4 receptor antagonist.
Published in: Biochem Pharmacol

Ligand: SC-41930 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.77 pKi
Reference (Journal): Blockade of human neutrophil activation by 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]propoxy]phenoxy]benzoic acid (LY293111), a novel leukotriene B4 receptor antagonist.
Published in: Biochem Pharmacol

Ligand: RO5101576 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.1 pIC50
Reference (Journal): Effects of LTB4 receptor antagonism on pulmonary inflammation in rodents and non-human primates.
Published in: Prostaglandins Other Lipid Mediat

Ligand: ONO-4057 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.43 pKi
Reference (Journal): ONO-4057, a novel, orally active leukotriene B4 antagonist: effects on LTB4-induced neutrophil functions.
Published in: Prostaglandins

Ligand: ONO-4057 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): ONO-4057, a novel, orally active leukotriene B4 antagonist: effects on LTB4-induced neutrophil functions.
Published in: Prostaglandins

Ligand: LY255283 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.6 pKi
Reference (Journal): Contribution of leukotriene B4 to airway inflammation and the effect of antagonists.
Published in: Ann N Y Acad Sci

Ligand: LTB4 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 9.4 pKi

Ligand: etalocib (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.75 pKi
Reference (Journal): Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studies.
Published in: J Pharmacol Exp Ther

Ligand: etalocib (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studies.
Published in: J Pharmacol Exp Ther

Ligand: CP-195543 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.62 pIC50
Reference (Journal): The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543.
Published in: J Pharmacol Exp Ther

Ligand: CP-195543 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.17 pKi
Reference (Journal): The preclinical pharmacological profile of the potent and selective leukotriene B4 antagonist CP-195543.
Published in: J Pharmacol Exp Ther

Ligand: CP105696 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.1 pIC50
Reference (Journal): The in vitro and in vivo pharmacologic activity of the potent and selective leukotriene B4 receptor antagonist CP-105696.
Published in: J Pharmacol Exp Ther

Ligand: BIIL 260 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.800000190734863 pKi
Reference (Journal): Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis.
Published in: Ann Rheum Dis

Ligand: BIIL 260 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.54 pIC50
Reference (Journal): Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis.
Published in: Ann Rheum Dis

Ligand: BIIL 260 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Primary target: no
Median affinity: 8.800000190734863 pKi
Reference (Journal): In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist.
Published in: J Pharmacol Exp Ther

Ligand: BIIL 260 (Synthetic organic)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.54 pIC50
Reference (Journal): In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist.
Published in: J Pharmacol Exp Ther

Ligand: 20-hydroxy-LTB4 (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.1 pKi
Reference (Journal): A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis.
Published in: Nature

Ligand: 12R-HETE (Metabolite)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.5 pKi
Reference (Journal): A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis.
Published in: Nature